Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


AavantiBio activates with $107m
Sarepta Therapeutics provided $15m in a series A round for the company, which is advancing University of Florida research.
SparingVision sees to new funding
Incubated by Vision Institute, the retinal disease gene therapy developer has secured $52.8m in a round co-led by UPMC Enterprises.
NetScientific picks up ProAxsis
QUB spinout ProAxsis has been fully acquired by NetScientific, which previously backed the company’s sole funding round in 2014.
Astellas takes an Iota in acquisition deal
The UC Berkeley spinout has been snapped up by Astellas, two years after the latter took part in its series A round.
Topas tackles $26m series B
Topas Therapeutics, which is exploiting University of Hamburg research, has pocketed $26m in its series B round.
Disarm hands itself to Eli Lilly
Eli Lilly will acquire the WUSTL-linked neurological disease therapy developer in a $135m deal that could top $1.2bn with milestone payments.
Daily deal net: October 16, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Codiak Biosciences cracks IPO code
Codiak – based on research at Gothenburg and MD Anderson Cancer Center – has succeeded in going public after previously cancelling plans.

Other News

TIAP absorbs state funding
The federal development board for Southern Ontario has injected $5m to accelerate the growth potential of TIAP's early-stage health sciences portfolio.
Ori derives $30m series A
Five years after being co-founded by UCL researchers, Ori Biotech has brought its overall funding to $41m.
Daily deal net: October 14, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Oxford Nanopore presses $108m
Oxford Nanopore has continued its funding streak with another $108m, bringing this year's haul to more than $208m and its overall total to around $800m.
Kronos Bio crushes IPO to raise $250m
MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.
Galecto elects to target $100m in IPO
Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.

Editor's Picks

When worlds collide – CVC interest in spinouts
Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
test reg